ReviewJAMA oncology2025
Management of Adult Acute Lymphoblastic Leukemia: A Review.
Review in JAMA oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.Blood research · 2026Review
- Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines.International journal of hematology · 2026Article
- Article
- Article
- Treatment of adult acute lymphoblastic leukemia-a therapeutic revolution in the making.Blood cancer journal · 2026Article
- Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.Cancer · 2026Article
- Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.Clinical lymphoma, myeloma & leukemia · 2026Article
- Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.Blood cancer journal · 2026Review
- Interleukin signaling mitigates the inhibitory effects of combined Src/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia.Haematologica · 2026Article
- [Comparative analysis of long-term efficacy between the CCCG-ALL-2015 and CCLG-ALL-2008 protocols in adolescents with acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Review
- Case Report: Clinical response to TKI therapy in T-cell acute lymphoblastic leukemia with rareFrontiers in oncology · 2026Article
- Nomogram-based prediction of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a retrospective study.Frontiers in pharmacology · 2026Article
- Article
- A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens.Cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Importance: Research in acute lymphoblastic leukemia (ALL) is translating into rapid changes in therapy and outcomes. Historically, adult ALL was treated with intensive chemotherapy extending over 2.5 to 3 years. This established tradition, accepted because of the high cure rates in childhood ALL, has been challenged by the development of highly active targeted therapies. Observation: Treatment modalities, combined with less and shorter chemotherapy durations, have produced better results than chemotherapy. The novel therapies include using the more potent BCR::ABL1 tyrosine kinase inhibitors (eg, ponatinib, dasatinib) with the bispecific CD3-CD19 T-cell engager antibody blinatumomab in Philadelphia chromosome-positive ALL and combining blinatumomab and/or inotuzumab (CD22 antibody drug conjugate) with standard chemotherapy in B-cell ALL. These have been associated with improved 4-year survival rates of 85% to 90% in Philadelphia chromosome-positive ALL and 80% to 85% in B-cell ALL. Conclusions and Relevance: The management of ALL is changing rapidly. Investigators have evaluated frontline and later-line regimens with combinations of tyrosine kinase inhibitors and immunotherapies with less or no chemotherapy. Future research will evaluate CD19, CD20, and CD22 multitargeting antibodies and chimeric antigen receptor T-cell therapies, new antibody formulations, and less intensive/shorter regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.